GlobeNewswire by notified

Blue Vision A/S – tildeling af fondsandele

Del

25. januar 2023
Årets meddelelse nr.: 8

Blue Vision A/S – tildeling af fondsandele

Med henvisning til blandt andet selskabsmeddelelse nr. 23 af 25. november 2022, og som led i den planlagte transaktion med Reponex Pharmaceuticals A/S, har bestyrelsen i Blue Vision A/S d.d. i henhold til bemyndigelsen i selskabets vedtægter § 4.1.E truffet beslutning om at forhøje selskabets aktiekapital med nominelt kr. 22.189.810 fordelt på 16.059.924 A-aktier á nominelt kr. 1 hver og 6.129.886 B-aktier á nominelt kr. 1 hver ved tildeling af fondsandele forholdsmæssigt til selskabets eksisterende aktionærer.  Ved tildelingen modtager de eksisterende aktionærer således vederlagsfrit en ny A-aktie for hver eksisterende A-aktie i Blue Vision A/S samt en ny B-aktie for hver eksisterende B-aktie i Blue Vision A/S.

De nye A-aktier vil efter registrering hos Erhvervsstyrelsen have samme rettigheder som de eksisterende A-aktier, og de nye B-aktier vil efter registrering hos Erhvervsstyrelsen have samme rettigheder som de eksisterende B-aktier.

De nye fondsandele og ændringer i Blue Vision's aktiekapital forventes registreret hos Erhvervsstyrelsen d.d., og de nye A-aktier forventes optaget til handel og officiel notering den 27. januar 2023.

Selskabets aktiekapital udgør herefter nominelt kr. 44.379.620 fordelt på 32.119.848 A-aktier á nominelt kr. 1 hver og 12.259.772 B-aktier á nominelt kr. 1 hver.

De nye fondsandele af samlet nominelt kr. 22.189.810 indbetales til kurs 100 og således kr. 1 pr. ny aktie af Blue Vision A/S ved overførsel af kr. 22.189.810 fra overført resultat fra selskabets seneste godkendte årsrapport for regnskabsåret 2021 reguleret for årets resultat i regnskabsåret 2022.

Årsagen til tildelingen af fondsandele er at kompensere de eksisterende aktionærer for resultat- og balanceforbedringer siden offentliggørelse af tilbudsdokumentet af 5. april 2022 til aktionærerne i Reponex Pharmaceuticals A/S samt mindske udvanding af de eksisterende aktionærer i forbindelse med den planlagte udstedelse af nye aktier i Blue Vision A/S til aktionærerne i Reponex Pharmaceuticals A/S. Der henvises til selskabsmeddelelse nr. 13 af 5. april 2022 for yderligere detaljer om overtagelsestilbuddet.

Tildeling sker automatisk til de eksisterende aktionærers konti hos Euronext Securities Copenhagen for så vidt angår de nye A-aktier, og via Euronext Securities Copenhagen (Issuer services) for så vidt angår de nye B-aktier.

Med venlig hilsen Blue Vision A/S

På bestyrelsens vegne

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Golar to acquire New Fortress Energy’s stake in FLNG Hilli6.2.2023 14:21:46 CET | Press release

Golar LNG Limited (“Golar” or “the Company”) has agreed to acquire the New Fortress Energy Inc. (“NFE”) ownership stake in FLNG Hilli in exchange for Golar’s remaining 4.1 million shares in NFE and $100 million in cash. Golar will also take over approximately $323 million in debt obligations linked to Hilli. Pursuant to the transaction, Golar will acquire the 50% interest in Trains 1 and 2 of FLNG Hilli, currently owned by a subsidiary of NFE. Following closing of the transaction, Golar’s effective interest in currently contracted FLNG Hilli earnings will be as follows: 94.55% of Common Units that receive tolling related fees relating to trains 1 and 2, and 5% of Dutch Title Transfer Facility (“TTF”) related fees,89.1% of Series A units that receive Brent oil related fees,89.1% of Series B units that receive 95% of TTF related fees. Following the transaction Golar will have no remaining shareholding in NFE. Commenting on the transaction, Golar CEO Karl Fredrik Staubo said “Today’s anno

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)6.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023. The Company recently announced positive results from the Phase 2a OLE at the 64th American Society of Hematology (ASH) Annual Meeting. “We are excited to share additional data from the OLE that further demonstrate the potential for SerpinPC to be a convenient subcutaneous treatment with a differentiated safety profile for people living with hemophilia,” said Saurabh Saha MD PhD, Chief Ex

Aktia’s Financial Statement Release 2023 will be published on Friday 17 February 2023 at 8.00 a.m.6.2.2023 14:00:00 CET | Press release

Aktia Bank Plc Press release 6 February 2023 at 03.00 p.m. Aktia’sFinancial Statement Release 2023 will be published on Friday17 February 2023 at 8.00 a.m. Aktia’s Financial Statement Release 2022 will be published on Friday 17 February 2023 at 8.00 a.m. (EET). The Financial Statement Release is available at Aktia’s website www.aktia.com after the publication. Webcast from the results event A live webcast will be sent from Aktia’s results event on Friday 17 February 2023 at 10.30 a.m. CEO Mikko Ayub and CFO Outi Henriksson will be presenting the results. The event will be held in English and can be seen live as a webcast or as a recording after the event at https://aktia.videosync.fi/2022-q4-results. The presentation material in English is available at Aktia’s website www.aktia.com before the results event. Aktia Bank Plc Further information: Lotta Borgström, Director, Investor Relations and Communications, tel. +358 10 247 6838, lotta.borgstrom@aktia.fi Distribution: Nasdaq Helsinki L

Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.006.2.2023 14:00:00 CET | Pressemelding

Aktia Bank Abp Pressmeddelande 6.2.2023 kl. 15.00 Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.00 Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.00. Bokslutskommunikén finns tillgänglig på Aktias webbplats på adressen www.aktia.com efter publiceringen. Webcast-sändning från resultattillställningen En direkt webcast-sändning arrangeras från Aktias resultattillställning fredagen 17.2.2023 kl. 10.30. Verkställande direktör Mikko Ayub och ekonomi- och finansdirektör Outi Henriksson presenterar resultatet. Tillställningen hålls på engelska och kan ses som en direkt webcast-sändning eller en inspelning efter tillställningen på adressen https://aktia.videosync.fi/2022-q4-results. Presentationsmaterialet på engelska finns tillgängligt på Aktias webbplats www.aktia.com före resultattillställningen. Aktia Bank Abp Mera information: Lotta Borgström, direktör för investerarrelationer och kommunikation, tfn 010 247 6838, lotta.borgstrom@aktia.fi

Bombardier CEO Éric Martel Evolves Leadership Team Structure as Part of Forward-Looking Growth Strategy, Building on Company Momentum6.2.2023 13:58:00 CET | Press release

Jean-Christophe Gallagher appointed Executive Vice President, Aircraft Sales and Bombardier Defense Paul Sislian appointed Executive Vice President of Bombardier Aftermarket Services & StrategyDavid Murray appointed Executive Vice President, Manufacturing, IT and Bombardier Operational Excellence SystemEric Filion joins Bombardier to the newly created role of Executive Vice President, Programs and Supply ChainMichel Ouellette will lead Engineering and Product Development until planned retirement later in 2023, following a 33-year, successful career MONTREAL, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Bombardier today announced a leadership team evolution that will focus on carrying forward the company’s positive momentum toward executing long-term growth and optimization strategies in the key areas of defense, services, continuous product improvement and next-generation manufacturing practices. “Bombardier has successfully embarked on its journey as a company focused on its world-class business